VivoSim Labs, Inc.(VIVS)Earnings, Financials & Key Ratios
VIVS•NASDAQ
Price updated Jun 19, 2026
AboutVivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.Show more
- Revenue$144K+32.1%
- EBITDA-$12M+16.6%
- Net Income-$2M+83.0%
- EPS (Diluted)-1.70+91.2%
- Gross Margin96.53%-3.5%
- EBITDA Margin-8576.39%+36.9%
- Operating Margin-8761.11%+36.7%
- Net Margin-1727.78%+87.2%
- ROE-35.31%+77.2%
VIVS Key Insights
VivoSim Labs, Inc. (VIVS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 33.2%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Sales declining 42.0% over 5 years
- ✗Shares diluted 92.1% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VIVS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VIVS Price & Volume
VivoSim Labs, Inc. (VIVS) stock price & volume — 10-year historical chart
Loading chart...
VIVS Growth Metrics
VivoSim Labs, Inc. (VIVS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-12.87%
5 Years-42.01%
3 Years-54.21%
TTM16.39%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM90.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM91.43%
Return on Capital
10 Years-79.25%
5 Years-92.61%
3 Years-126.55%
Last Year-163.82%
VIVS Peer Comparison
VivoSim Labs, Inc. (VIVS) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMNM | 1.79B | 18.74 | -7.71 | -23.23% | -55.94% | -51.15% | 0.01 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RXRX | 1.44B | 3.23 | -2.24 | 26.92% | -8.44% | -54.32% | 0.07 | |
 SDGR | 1.18B | 15.76 | -11.18 | 23.29% | -40.6% | -30.85% | 0.30 | |
 ABSI | 1.16B | 7.41 | -8.82 | -38.24% | -64.51% | -63.58% | 0.03 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 SEER | 95.67M | 1.74 | -1.36 | 15.57% | -468.74% | -26.58% | 0.09 |
Compare VIVS vs Peers
VivoSim Labs, Inc. (VIVS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VIVS Income Statement
VivoSim Labs, Inc. (VIVS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 4.23M | 4.6M | 3.09M | 2.2M | 0 | 1.5M | 370K | 109K | 144K | 142K |
Revenue Growth % | 185.23% | 8.82% | -32.85% | -28.95% | -100% | - | -75.33% | -70.54% | 32.11% | 16.39% |
Cost of Goods Sold | 956K | 1.03M | 482K | 328K | 0 | 0 | 0 | 0 | 5K | 0 |
COGS % of Revenue | 22.6% | 22.38% | 15.59% | 14.94% | - | - | - | - | 3.47% | - |
Gross Profit | 3.27M▲ 0% | 3.57M▲ 9.1% | 2.61M▼ 27.0% | 1.87M▼ 28.4% | 0▼ 100.0% | 1.5M▲ 0% | 370K▼ 75.3% | 109K▼ 70.5% | 139K▲ 27.5% | 142K▲ 0% |
Gross Margin % | 77.4% | 77.62% | 84.41% | 85.06% | - | 100% | 100% | 100% | 96.53% | 100% |
Gross Profit Growth % | 120.77% | 9.13% | -26.98% | -28.4% | -100% | - | -75.33% | -70.54% | 27.52% | - |
Operating Expenses | 41.85M | 38.84M | 29.88M | 23.34M | 16.83M | 12.98M | 18.1M | 15.2M | 12.76M | 11.6M |
OpEx % of Revenue | 989.34% | 843.88% | 966.77% | 1062.98% | - | 865.27% | 4892.16% | 13940.37% | 8857.64% | - |
Selling, General & Admin | 22.3M | 20.89M | 14.7M | 17.15M | 15.71M | 9.63M | 9.09M | 9.64M | 7.69M | 7.66M |
SG&A % of Revenue | 527.28% | 453.79% | 475.64% | 780.97% | - | 642.07% | 2456.22% | 8847.71% | 5340.97% | - |
Research & Development | 19.55M | 17.96M | 14.75M | 5.28M | 1.1M | 3.32M | 8.88M | 5.5M | 5.03M | 3.92M |
R&D % of Revenue | 462.06% | 390.09% | 477.26% | 240.62% | - | 221.33% | 2401.35% | 5044.04% | 3489.58% | - |
Other Operating Expenses | 0 | 0 | 429K | 909K | 15K | 28K | 128K | 53K | 39K | 16K |
Operating Income | -38.58M▲ 0% | -35.27M▲ 8.6% | -27.27M▲ 22.7% | -21.48M▲ 21.3% | -16.83M▲ 21.6% | -11.48M▲ 31.8% | -17.73M▼ 54.5% | -15.09M▲ 14.9% | -12.62M▲ 16.4% | -11.45M▲ 0% |
Operating Margin % | -911.94% | -766.26% | -882.37% | -977.91% | - | -765.27% | -4792.16% | -13840.37% | -8761.11% | -8066.2% |
Operating Income Growth % | 0.18% | 8.57% | 22.67% | 21.26% | 21.65% | 31.78% | -54.46% | 14.92% | 16.37% | - |
EBITDA | -37.43M | -34M | -26.29M | -20.33M | -16.79M | -11.34M | -17.44M | -14.81M | -12.35M | -11.22M |
EBITDA Margin % | -884.78% | -738.74% | -850.66% | -925.91% | - | -755.8% | -4712.97% | -13583.49% | -8576.39% | -7902.11% |
EBITDA Growth % | 1.06% | 9.14% | 22.67% | 22.67% | 17.45% | 32.46% | -53.81% | 15.09% | 16.59% | 8.64% |
D&A (Non-Cash Add-back) | 1.15M | 1.27M | 980K | 1.14M | 41K | 142K | 293K | 280K | 266K | 233K |
EBIT | -38.58M | -35.27M | -27.27M | -21.48M | -16.83M | -11.48M | -17.73M | -15.09M | -2.48M | -1.21M |
Net Interest Income | 198K | 478K | 705K | 594K | 15K | 8K | 454K | 405K | 130K | 229K |
Interest Income | 198K | 478K | 705K | 594K | 15K | 8K | 454K | 405K | 140K | 242K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K | 13K |
Other Income/Expense | 151K | 470K | 642K | 2.77M | 2K | 33K | 474K | 417K | 10.13M | 10.23M |
Pretax Income | -38.42M▲ 0% | -34.8M▲ 9.4% | -26.63M▲ 23.5% | -18.71M▲ 29.8% | -16.82M▲ 10.1% | -11.45M▲ 32.0% | -17.26M▼ 50.8% | -14.67M▲ 15.0% | -2.49M▲ 83.1% | -1.23M▲ 0% |
Pretax Margin % | -908.37% | -756.05% | -861.6% | -851.91% | - | -763.07% | -4664.05% | -13457.8% | -1726.39% | -862.68% |
Income Tax | 23K | 2K | 3K | 2K | 2K | 2K | 2K | 2K | 2K | 2K |
Effective Tax Rate % | -0.06% | -0.01% | -0.01% | -0.01% | -0.01% | -0.02% | -0.01% | -0.01% | -0.08% | -0.16% |
Net Income | -38.45M▲ 0% | -34.8M▲ 9.5% | -26.64M▲ 23.5% | -18.71M▲ 29.8% | -16.83M▲ 10.1% | -11.45M▲ 32.0% | -17.26M▼ 50.8% | -14.67M▲ 15.0% | -2.49M▲ 83.0% | -1.23M▲ 0% |
Net Margin % | -908.91% | -756.09% | -861.7% | -852% | - | -763.2% | -4664.59% | -13459.63% | -1727.78% | -864.08% |
Net Income Growth % | 0.33% | 9.48% | 23.47% | 29.75% | 10.07% | 31.96% | -50.76% | 15% | 83.04% | 90.09% |
Net Income (Continuing) | -38.45M | -34.8M | -26.64M | -18.71M | -16.83M | -11.45M | -17.26M | -14.67M | -2.49M | -1.23M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -94.38▲ 0% | -77.89▲ 17.5% | -55.40▲ 28.9% | -34.66▲ 37.4% | -29.25▲ 15.6% | -15.78▲ 46.1% | -23.77▼ 50.6% | -19.25▲ 19.0% | -1.70▲ 91.2% | -0.84▲ 0% |
EPS Growth % | 8.19% | 17.47% | 28.87% | 37.44% | 15.61% | 46.05% | -50.63% | 19.02% | 91.17% | 91.43% |
EPS (Basic) | -94.38 | -77.89 | -55.40 | -34.66 | -29.25 | -15.78 | -23.77 | -19.25 | -1.70 | - |
Diluted Shares Outstanding | 407.35K | 446.85K | 480.75K | 539.82K | 575.17K | 725.3K | 726.09K | 762.08K | 1.46M | 1.46M |
Basic Shares Outstanding | 407.35K | 446.85K | 480.75K | 539.82K | 575.17K | 725.3K | 726.09K | 762.08K | 1.46M | 1.46M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VIVS Balance Sheet
VivoSim Labs, Inc. (VIVS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 65.09M | 46.76M | 38.57M | 28.32M | 38.4M | 29.53M | 17.05M | 3.94M | 12.13M | 6.04M |
Cash & Short-Term Investments | 62.75M | 43.73M | 36.48M | 27.36M | 37.36M | 28.68M | 16.01M | 2.9M | 11.31M | 4.29M |
Cash Only | 62.75M | 43.73M | 36.48M | 27.36M | 37.36M | 28.68M | 15.3M | 2.9M | 11.31M | 4.29M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 706K | 0 | 0 | 0 |
Accounts Receivable | 647K | 1.03M | 558K | 111K | 0 | 0 | 152K | 33K | 30K | 1.04M |
Days Sales Outstanding | 55.83 | 81.52 | 65.89 | 18.45 | - | - | 149.95 | 110.5 | 76.04 | 731.29 |
Inventory | 550K | 842K | 490K | 0 | 0 | 0 | 0 | 297K | 0 | 0 |
Days Inventory Outstanding | 209.99 | 298.38 | 371.06 | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 69K | 4K | 12K | 709K |
Total Non-Current Assets | 4.09M | 3.07M | 2.05M | 123K | 1.52M | 3.76M | 3.27M | 2.41M | 2.52M | 919K |
Property, Plant & Equipment | 3.84M | 2.79M | 1.83M | 0 | 381K | 2.81M | 2.61M | 1.97M | 1.29M | 773K |
Fixed Asset Turnover | 1.10x | 1.65x | 1.69x | - | - | 0.53x | 0.14x | 0.06x | 0.11x | 0.14x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 248K | 279K | 217K | 123K | 1.14M | 948K | 658K | 445K | 1.23M | 146K |
Total Assets | 69.18M▲ 0% | 49.83M▼ 28.0% | 40.62M▼ 18.5% | 28.44M▼ 30.0% | 39.92M▲ 40.4% | 33.3M▼ 16.6% | 20.31M▼ 39.0% | 6.35M▼ 68.7% | 14.65M▲ 130.7% | 6.96M▲ 0% |
Asset Turnover | 0.06x | 0.09x | 0.08x | 0.08x | - | 0.05x | 0.02x | 0.02x | 0.01x | 0.01x |
Asset Growth % | 2.37% | -27.97% | -18.47% | -29.99% | 40.35% | -16.59% | -38.99% | -68.74% | 130.75% | 281.7% |
Total Current Liabilities | 6.01M | 4.66M | 3.74M | 1.81M | 721K | 1.38M | 3.67M | 1.86M | 3.74M | 2.48M |
Accounts Payable | 1.17M | 464K | 628K | 720K | 281K | 415K | 331K | 627K | 1.64M | 671K |
Days Payables Outstanding | 447.09 | 164.43 | 475.56 | 801.22 | - | - | - | - | 120.01K | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 582K | 668K | 525K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.48M | 2.92M | 2.19M | 829K | 378K | 434K | 609K | 536K | 998K | 685K |
Current Ratio | 10.83x | 10.04x | 10.32x | 15.65x | 53.26x | 21.35x | 4.64x | 2.12x | 3.25x | 2.44x |
Quick Ratio | 10.74x | 9.86x | 10.19x | 15.65x | 53.26x | 21.35x | 4.64x | 1.96x | 3.25x | 2.44x |
Cash Conversion Cycle | -181.27 | 215.47 | -38.61 | - | - | - | - | - | - | 731.29 |
Total Non-Current Liabilities | 807K | 583K | 588K | 0 | 0 | 1.7M | 1.31M | 888K | 421K | 44K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 1.7M | 1.31M | 888K | 421K | 935K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 749K | 564K | 588K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6.82M | 5.24M | 4.33M | 1.81M | 721K | 3.09M | 4.98M | 2.75M | 4.16M | 2.52M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 2.18M | 1.8M | 1.39M | 942K | 577K |
Net Debt | -62.75M | -43.73M | -36.48M | -27.36M | -37.36M | -26.49M | -13.5M | -1.51M | -10.37M | -3.71M |
Debt / Equity | - | - | - | - | - | 0.07x | 0.12x | 0.39x | 0.09x | 0.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.05x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.33x |
Interest Coverage | - | - | - | - | - | - | - | - | -247.60x | -93.23x |
Total Equity | 62.36M▲ 0% | 44.59M▼ 28.5% | 36.3M▼ 18.6% | 26.63M▼ 26.6% | 39.2M▲ 47.2% | 30.21M▼ 22.9% | 15.33M▼ 49.3% | 3.6M▼ 76.5% | 10.49M▲ 191.4% | 4.44M▲ 0% |
Equity Growth % | 0.29% | -28.5% | -18.59% | -26.63% | 47.18% | -22.93% | -49.26% | -76.51% | 191.36% | 1446.57% |
Book Value per Share | 153.09 | 99.78 | 75.50 | 49.33 | 68.15 | 41.65 | 21.11 | 4.73 | 7.17 | 3.03 |
Total Shareholders' Equity | 62.36M | 44.59M | 36.3M | 26.63M | 39.2M | 30.21M | 15.33M | 3.6M | 10.49M | 4.44M |
Common Stock | 104K | 111K | 124K | 7K | 9K | 9K | 9K | 10K | 2K | 3K |
Retained Earnings | -199.32M | -234.12M | -260.75M | -279.46M | -296.29M | -307.74M | -325M | -339.67M | -342.16M | -350.24M |
Treasury Stock | 0 | 0 | 0 | 0 | -1K | -1K | -1K | -1K | -1K | 0 |
Accumulated OCI | -11K | 0 | 0 | 0 | 0 | 0 | 2K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VIVS Cash Flow Statement
VivoSim Labs, Inc. (VIVS) cash flow — operating, investing & free cash flow history
| Metric | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -29.18M | -28.86M | -20.38M | -14.88M | -13.32M | -8.45M | -12.41M | -14.65M | -9.46M | -10.62M |
Operating CF Margin % | -689.95% | -626.92% | -659.17% | -677.69% | - | -563.53% | -3353.51% | -13443.12% | -6570.14% | - |
Operating CF Growth % | 0.62% | 1.12% | 29.39% | 26.96% | 10.48% | 36.55% | -46.79% | -18.09% | 35.43% | -24.37% |
Net Income | -38.45M | -34.8M | -26.64M | -18.71M | -16.83M | -11.45M | -17.26M | -14.67M | -2.49M | -1.23M |
Depreciation & Amortization | 1.15M | 1.27M | 980K | 1.14M | 41K | 142K | 293K | 280K | 266K | 233K |
Stock-Based Compensation | 7.39M | 6.9M | 5.19M | 4.11M | 5.56M | 2.26M | 2.38M | 1.51M | 532K | 236K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 52K | 21K | 63K | -424K | 19K | 0 | -125K | -154K | -8.81M | -9.26M |
Working Capital Changes | 669K | -2.25M | 24K | -998K | -2.11M | 597K | 2.31M | -1.62M | 1.04M | -607K |
Change in Receivables | -388K | -381K | 470K | 447K | 111K | 0 | -152K | 119K | 3K | -7K |
Change in Inventory | -216K | -292K | 352K | 276K | 0 | 0 | 0 | -297K | -501K | 0 |
Change in Payables | 384K | -707K | 164K | 92K | -439K | 134K | -148K | 296K | 1.02M | -166K |
Cash from Investing | -1.39M | -292K | -76K | 747K | -393K | -409K | -966K | 816K | 9.03M | 9M |
Capital Expenditures | -1.35M | -226K | -79K | 0 | -405K | -409K | -396K | -42K | -13K | 9M |
CapEx % of Revenue | 32.01% | 4.91% | 2.56% | - | - | 27.27% | 107.03% | 38.53% | 9.03% | 6338.03% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -37K | -66K | 3K | 747K | 12K | 0 | 0 | 0 | 9M | 0 |
Cash from Financing | 31.25M | 10.11M | 13.15M | 4.93M | 23.84M | 205K | 0 | 1.44M | 8.85M | 4.75M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 30.66M | 9.38M | 13.33M | 5M | 23.8M | 251K | 0 | 1.44M | 8.85M | 5M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -1K | 0 | 0 | 0 | 0 | 0 |
Other Financing | 582K | 732K | -173K | -61K | 38K | -46K | 0 | 0 | 0 | -246K |
Net Change in Cash | 660K▲ 0% | -19.02M▼ 2982.6% | -7.3M▲ 61.6% | -9.2M▼ 26.1% | 10.12M▲ 210.0% | -8.66M▼ 185.6% | -13.37M▼ 54.5% | -12.4M▲ 7.3% | 8.41M▲ 167.8% | 3.13M▲ 0% |
Free Cash Flow | -30.54M▲ 0% | -29.15M▲ 4.5% | -20.45M▲ 29.8% | -14.88M▲ 27.2% | -13.73M▲ 7.8% | -8.86M▲ 35.4% | -12.8M▼ 44.5% | -14.7M▼ 14.8% | -9.47M▲ 35.5% | -10.62M▲ 0% |
FCF Margin % | -721.96% | -633.35% | -661.73% | -677.69% | - | -590.8% | -3460.54% | -13481.65% | -6579.17% | -7481.69% |
FCF Growth % | 3.1% | 4.54% | 29.84% | 27.24% | 7.75% | 35.45% | -44.48% | -14.77% | 35.53% | -5.08% |
FCF per Share | -74.97 | -65.24 | -42.55 | -27.57 | -23.87 | -12.22 | -17.63 | -19.28 | -6.47 | -7.26 |
FCF Conversion (FCF/Net Income) | 0.76x | 0.83x | 0.76x | 0.80x | 0.79x | 0.74x | 0.72x | 1.00x | 3.80x | 8.66x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K | 8K |
Taxes Paid | 23K | 2K | 3K | 2K | 2K | 2K | 2K | 2K | 2K | 0 |
VIVS Key Ratios
VivoSim Labs, Inc. (VIVS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -61.74% | -65.08% | -65.86% | -59.46% | -51.12% | -32.99% | -75.8% | -155% | -35.31% | -15.56% |
Return on Invested Capital (ROIC) | - | -11232.8% | -6007.49% | - | -2279.95% | -310.3% | -479.22% | -576.24% | -853.97% | -1058.92% |
Gross Margin | 77.4% | 77.62% | 84.41% | 85.06% | - | 100% | 100% | 100% | 96.53% | 100% |
Net Margin | -908.91% | -756.09% | -861.7% | -852% | - | -763.2% | -4664.59% | -13459.63% | -1727.78% | -864.08% |
Debt / Equity | - | - | - | - | - | 0.07x | 0.12x | 0.39x | 0.09x | 0.13x |
Interest Coverage | - | - | - | - | - | - | - | - | -247.60x | -93.23x |
FCF Conversion | 0.76x | 0.83x | 0.76x | 0.80x | 0.79x | 0.74x | 0.72x | 1.00x | 3.80x | 8.66x |
Revenue Growth | 185.23% | 8.82% | -32.85% | -28.95% | -100% | - | -75.33% | -70.54% | 32.11% | 16.39% |
Related:VIVS Dividend History·VIVS Revenue History·VIVS Price History·VIVS P/E History·VIVS Financial Ratios·VIVS Institutional Holders
VIVS Frequently Asked Questions
VivoSim Labs, Inc. (VIVS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
VivoSim Labs, Inc. (VIVS) reported $0.1M in revenue for fiscal year 2025.
VivoSim Labs, Inc. (VIVS) grew revenue by 32.1% over the past year. This is strong growth.
VivoSim Labs, Inc. (VIVS) reported a net loss of $1.2M for fiscal year 2025.
Dividend & Returns
VivoSim Labs, Inc. (VIVS) has a return on equity (ROE) of -35.3%. Negative ROE indicates the company is unprofitable.
VivoSim Labs, Inc. (VIVS) had negative free cash flow of $10.6M in fiscal year 2025, likely due to heavy capital investments.